During Thursday’s Current trade, Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO), lost -2.99% to $18.06.
Halozyme Therapeutics, Inc. (HALO) declared the Pancreas Center at the University of California, San Francisco (UCSF) has initiated a clinical research study of Halozyme’s investigational new drug, PEGPH20 in pancreatic cancer patients who are candidates for potentially curative surgery. The trial will be conducted within the UCSF Helen Diller Family Comprehensive Cancer Center.
The Phase 2 study will investigate PEGPH20 in combination with gemcitabine and nab-paclitaxel (ABRAXANE) in patients with borderline resectable Pancreatic Ductal Adenocarcinoma (PDAC). The study will track the progress of up to 36 patients through chemotherapy and surgical treatment.
PEGPH20 (PEGylated recombinant human hyaluronidase) targets the degradation of hyaluronan (HA), a chain of natural sugars that can accumulate around cancer cells, inhibiting other therapies. By degrading HA, PEGPH20 may enhance the access of co-administered chemotherapeutic and immunotherapeutic agents.
Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter abnormal tissue structures for clinical benefit.
Shares of CTI BioPharma Corp (NASDAQ:CTIC), declined -2.35% to $1.66, during its current trading session.
CTI BioPharma Corp. (CTIC) declared findings from an investigator-sponsored Phase 2 trial in patients with either primary (de novo) acute myeloid leukemia (AML) or AML that has evolved from myelodysplastic syndrome (MDS). Results showed the combination of tosedostat with low dose cytarabine/Ara-C (LDAC) resulted in an overall response rate (ORR) of 54 percent in elderly patients with AML – with 45 percent of patients achieving durable complete responses (CR). These final results were presented by Dr. Giuseppe Visani, Director of Hematology and Stem Cell Transplant Center at AORMN, Pesaro, Italy in a poster session (abstract #P564) during the 20th Congress of the European Hematology Association (EHA), June 11-14, 2015 in Vienna, Austria.
AML is the most common acute leukemia affecting adults, and its incidence enhances with age. AML may develop from the progression of other diseases, such as MDS, which is a blood cancer that also affects the bone marrow and leads to a decrease in circulating red blood cells. Tosedostat is a potential first-in-class selective inhibitor of aminopeptidases, which are required by tumor cells to provide amino acids necessary for growth and tumor cell survival.
CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an oral multikinase inhibitor with activity against Janus Kinase 2 and FMS-like tyrosine kinase, which is in Phase III clinical trials for the treatment of myelofibrosis. In addition, it is developing Tosedostat, an oral once-daily aminopeptidase inhibitor that is in Phase II/III clinical trials for the treatment of acute myeloid leukemia; and Opaxio, a chemotherapeutic agent, which is in Phase III clinical trials for the treatment of various solid tumors, counting non-small cell lung, ovarian, breast, and prostate cancers.
Qunar Cayman Islands Ltd (NASDAQ:QUNR), during its Thursday’s current trading session decreased -8.71% to $32.89.
Qunar Cayman Islands Limited (QUNR) declared that it has received the final judgment (the “Final Judgment”) from the Beijing High People’s Court (the “Court”) with respect to the contract dispute regarding an Inventory Distribution Agreement for hotels with eLong, Inc., which was formerly described in the Company’s annual report on Form 20-F for the fiscal year of 2014. The Company does not believe that the Final Judgment will have any material impact on its future business, results of operations or financial condition.
In the Final Judgment, the Court upheld the preceding judgment of the Beijing No. 1 Intermediate People’s Court from January 1, 2015 that (i) our partner, Beijing Qunar Software Technology Co., Ltd. (“Beijing Qunar”) shall credit to the advertisement account opened at Beijing Qunar by eLongNet Information Technology (Beijing) Co., Ltd. (“eLongNet”), a partner of eLong, Inc., the amount of RMB52,335,369 (about US$8.5 million) corresponding to the period up to September 30, 2014; and RMB36,450,000 (about US$6.0 million) for the period from October 1, 2014 through June 30, 2015; (ii) eLongNet shall pay Beijing Qunar a commission of RMB8,127,400 (about US$1.3 million) due under the Inventory Distribution Agreement; and (iii) the Inventory Distribution Agreement shall continue to be performed by both parties. The Court also ordered Beijing Qunar to pay eLongNet RMB227,599 (US$37 thousand) in legal fees, and apportioned court fees between the parties.
Qunar Cayman Islands Limited operates an online travel commerce platform in the Peoples Republic of China. The company through its platform provides a range of travel products comprising flight tickets, hotels, vacation packages, and attraction tickets, in addition to display advertising, train tickets, car services, smart lodging, and other services. Its customers comprise flight travel service providers, airlines, independent hotels, online travel agencies, insurance service providers, and others.
Finally, Apollo Investment Corp. (NASDAQ:AINV), decreased -0.91%, to $6.55.
Apollo Investment Corporation (AINV) declared financial results for its first fiscal quarter ended June 30, 2015. The Company’s net investment income was $0.22 per share for the quarter ended June 30, 2015, contrast to $0.22 for the quarter ended March 31, 2015. The Company’s net asset value (“NAV”) was $8.01 per share as of June 30, 2015, contrast to $8.18, as of March 31, 2015.
Additionally, the Company also declared that its Board of Directors has declared a dividend of $0.20 per share for the first fiscal quarter of 2016, payable on October 6, 2015 to stockholders of record as of September 21, 2015. The specific tax characteristics of this dividend will be stated to stockholders on Form 1099 after the end of the calendar year.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
